{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:50:00Z","timestamp":1771235400594,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T00:00:00Z","timestamp":1554249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s00345-019-02741-7","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T03:19:01Z","timestamp":1554347941000},"page":"111-119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5767-0548","authenticated-orcid":false,"given":"Neal","family":"Shore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Mincik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"DeGuenther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Vladimir","family":"Student","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mindaugas","family":"Jievaltas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jitka","family":"Patockova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelle","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chu-Hsuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Tsung","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yisheng","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,3]]},"reference":[{"issue":"1","key":"2741_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7\u201330","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2741_CR2","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.eururo.2008.09.024","volume":"55","author":"A Morgentaler","year":"2009","unstructured":"Morgentaler A, Traish AM (2009) Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 55(2):310\u2013320","journal-title":"Eur Urol"},{"issue":"1","key":"2741_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0022-5347(05)64820-3","volume":"168","author":"C Huggins","year":"2002","unstructured":"Huggins C, Hodges CV (2002) Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 168(1):9\u201312","journal-title":"J Urol."},{"key":"2741_CR4","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Prostate Cancer. Version 2.2018\u2014March 8, 2018. \nhttp:\/\/NCCN.org\n\n. Accessed 5 Sep 2018"},{"issue":"5","key":"2741_CR5","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1073\/pnas.79.5.1658","volume":"79","author":"G Tolis","year":"1982","unstructured":"Tolis G, Ackman D, Stellos A, Mehta A, Labrie F, Fazekas AT et al (1982) Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci USA 79(5):1658\u20131662","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2741_CR6","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/0006-291X(74)90219-8","volume":"60","author":"M Fujino","year":"1974","unstructured":"Fujino M, Fukuda T, Shinagawa S, Kobayashi S, Yamazaki I (1974) Synthetic analogs of luteinizing hormone releasing hormone (LH\u2013RH) substituted in position 6 and 10. Biochem Biophys Res Commun 60(1):406\u2013413","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"2741_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1056\/NEJM199101103240205","volume":"324","author":"PM Conn","year":"1991","unstructured":"Conn PM, Crowley WF Jr (1991) Gonadotropin-releasing hormone and its analogues. N Engl J Med 324(2):93\u2013103","journal-title":"N Engl J Med"},{"issue":"2","key":"2741_CR8","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0022-5347(05)00161-8","volume":"175","author":"ED Crawford","year":"2006","unstructured":"Crawford ED, Sartor O, Chu F, Perez R, Karlin G, Garrett JS (2006) A 12-month clinical study of LA-2585 (45.0\u00a0mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol. 175(2):533\u2013536","journal-title":"J Urol."},{"issue":"7","key":"2741_CR9","doi-asserted-by":"publisher","first-page":"566","DOI":"10.7326\/0003-4819-132-7-200004040-00009","volume":"132","author":"J Seidenfeld","year":"2000","unstructured":"Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL et al (2000) Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 132(7):566\u2013577","journal-title":"Ann Intern Med"},{"issue":"1\u20132","key":"2741_CR10","first-page":"1","volume":"14","author":"H Lepor","year":"2012","unstructured":"Lepor H, Shore ND (2012) LHRH agonists for the treatment of prostate cancer: 2012. Rev Urol. 14(1\u20132):1\u201312","journal-title":"Rev Urol."},{"issue":"10","key":"2741_CR11","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1201546","volume":"367","author":"JM Crook","year":"2012","unstructured":"Crook JM, O\u2019Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM et al (2012) Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 367(10):895\u2013903","journal-title":"N Engl J Med"},{"issue":"14","key":"2741_CR12","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","volume":"368","author":"M Hussain","year":"2013","unstructured":"Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G et al (2013) Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368(14):1314\u20131325","journal-title":"N Engl J Med"},{"issue":"2","key":"2741_CR13","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.eururo.2013.03.055","volume":"66","author":"F Calais da Silva","year":"2014","unstructured":"Calais da Silva F, Calais da Silva FM, Goncalves F, Santos A, Kliment J, Whelan P et al (2014) Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group. Eur Urol. 66(2):232\u2013239","journal-title":"Eur Urol."},{"issue":"Suppl 5","key":"2741_CR14","first-page":"S3","volume":"7","author":"H Lepor","year":"2005","unstructured":"Lepor H (2005) Comparison of single-agent androgen suppression for advanced prostate cancer. Rev Urol. 7(Suppl 5):S3\u2013S12","journal-title":"Rev Urol."},{"key":"2741_CR15","unstructured":"Eligard\u00ae (Leuprolide acetate for injection). Product Monograph. \nhttp:\/\/products.sanofi.ca\/en\/eligard.pdf\n\n. Accessed 5 Sep 2018"},{"issue":"4","key":"2741_CR16","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","volume":"71","author":"P Cornford","year":"2017","unstructured":"Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T et al (2017) EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 71(4):630\u2013642","journal-title":"Eur Urol."},{"issue":"3\u20134","key":"2741_CR17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1159\/000324707","volume":"80","author":"M Markman","year":"2011","unstructured":"Markman M (2011) Cross-trial comparisons in the oncology arena: when is this justified? Oncology. 80(3\u20134):151\u2013152","journal-title":"Oncology."},{"issue":"1","key":"2741_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/pcan.2011.50","volume":"15","author":"A Spitz","year":"2012","unstructured":"Spitz A, Young JM, Larsen L, Mattia-Goldberg C, Donnelly J, Chwalisz K (2012) Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer. Prostate Cancer Prostatic Dis 15(1):93\u201399","journal-title":"Prostate Cancer Prostatic Dis"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-019-02741-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-019-02741-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-019-02741-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T12:13:36Z","timestamp":1585916016000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-019-02741-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,3]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["2741"],"URL":"https:\/\/doi.org\/10.1007\/s00345-019-02741-7","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,3]]},"assertion":[{"value":"11 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Neal Shore has no conflicts of interest to disclose. Ivan Mincik has no conflicts of interest to disclose. Mark DeGuenther has no conflicts of interest to disclose. Vladimir Student Jr has no conflicts of interests to disclose. Mingdaugas Jievaltas has no conflicts of interest to disclose. Jitka Patockova reports personal fees from QPS Holdings as a medical monitor for QPS Holdings, LLC which is the CRO for the published study. Kelle Simpson reports personal fees as a project manager for QPS Holdings, LLC which is the CRO for the published study. Yisheng Lee reports personal fees from Foresee Pharmaceuticals during the study; as the chief medical officer for Foresee Pharmaceuticals, LLC which is the sponsor for the published study. Ben Chien reports personal fees from Foresee Pharmaceuticals as a President and CEO for Foresee Pharmaceuticals, LLC which is the sponsor for the published study. Chu-Hsuan Hu reports personal fees from QPS Holdings, LLC as and chief statistician for QPS Holdings, LLC which is the CRO for the published study. Shih-Tsung Huang reports personal fees from QPS Holdings LLD as chief medical officer for QPS Holdings, LLC which is the CRO for the published study. Yuhua Li reports personal fees from Foresee Pharmaceuticals, as vice president and chief manager for SIF technology for Foresee Pharmaceuticals, LLC which is the sponsor for the published study. John Mao reports personal fees from Foresee Pharmaceuticals as Vice president and chief manager for product development for Foresee Pharmaceuticals, LLC which is the sponsor for the published study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"A properly executed written informed consent was obtained from each subject prior to the enrollment into the study and prior to the performance of any procedure related to the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All procedures performed in the study involving human participants was in accordance with the ethical standards of the institutional and ICH-GCP and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}